Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
Nov 15, 2026, 20:55

Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease

Martin Holst Lange, Executive Vice President of Research and Development, Chief Scientific Officer at Novo Nordisk, shared a post on LinkedIn:

“Sickle cell disease is a lifelong condition that can mean severe pain, persistent fatigue and uncertainty about what tomorrow will bring.

For a community that has faced limited treatment options and longstanding inequalities in care, continued innovation that can support better, lasting health is critical.

Today, Novo announces the regulatory submissions of etavopivat to the US Food and Drug Administration and the European Medicines Agency, taking an important step towards a potential new once-daily oral treatment for adolescents and adults aged 12 years and older living with sickle cell disease.

The submissions build on results from the phase 3 HIBISCUS trial, which showed fewer painful crises and improvements in haemoglobin levels vs. placebo, two important aspects of sickle cell disease.

From the beginning, people living with sickle cell disease have helped shape this programme by sharing their experiences and what they need from a new treatment.

To everyone who took part in the trials, their families and the clinical teams who supported them: thank you. This progress would not be possible without you.

And thank you to colleagues across Novo Nordisk for the years of work and determination that brought us to this milestone.

Ultimately, this is about giving people living with sickle cell disease more treatment options and greater freedom in their everyday lives.”

Martin Holst Lange

Stay updated with Hemostasis Today.